Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients

What Was Tested

Researchers studied Octreotide and Somatostatin in this clinical trial publication.

In all patients, [(18)F]FDG-PET/CT was performed to determine recurrent disease with enhanced glucose metabolism, and (68)Ga-DOTATOC PET/CT was used to identify SSTR expression.

Why It Was Studied

The expression of somatostatin receptors (SSTR) in thyroid cells may offer the possibility to identify metastatic lesions and to select patients for peptide receptor radionuclide therapy (PRRT).

Who Took Part

The abstract describes 41 patients taking part.

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.

The researchers enrolled 41 patients with progressive radioiodine-negative DTC (24 women and 17 men; mean age=54.3 years, median=59 years, range=19-78 years).

Eleven patients were treated with PRRT receiving a fractionated injection of 1.5-3.7 GBq (90)Y-DOTATOC/administration.

How the Study Was Run

Dosimetric evaluation was performed with (111)In-DOTATOC scintigraphy.

Parameters provided by (68)Ga-DOTATOC PET/CT were analyzed as potential therapeutic predictors to differentiate responding from nonresponding.

What Was Measured

Topics PubMed links to this paper include Fluorodeoxyglucose F18, Octreotide, Organometallic Compounds, Positron-Emission Tomography, Radiopharmaceuticals, Receptors, Somatostatin and Somatostatin.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin in 41 patients.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Thyroid : official journal of the American Thyroid Association), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.